Abarelix (R3827; PPI 149) is a potent gonadotrophin-releasing hormone (GnRH) antagonist, used for prostate cancer treatment.
体外研究
Abarelix (30 and 300 µg/mL) causes significantly increased histamine release. Abarelix is the first
GnRH antagonist to be developed, and can produce rapid and sustained decreases in testosterone to castrate levels without the need for co-administration of an antiandrogen, and with a very low complication rate in the short term. Abarelix demonstrates to promptly and substantially reduce follicle-stimulating hormone levels to lower than LHRH agonist. Abarelix does not cause a surge in serum testosterone that can precipitate a flare phenomenon or worsening of disease, particularly dangerous for patients with metastatic, symptomatic disease, and produces medical castration more quickly.
分子式
C72H95N14O14Cl
分子量
1416.06
CAS号
183552-38-7
中文名称
阿巴瑞克
运输条件
Room temperature in continental US; may vary elsewhere.